Alembic Pharmaceuticals Limited — Others, 06-08-2025: Copy of Newspaper Publication

Alembic Pharmaceuticals has announced the financial results for the quarter ended June 30, 2025. Consolidated total income from operations rose to ₹1,710.72 Cr, up from ₹1,561.73 Cr in the previous year's same quarter. Net profit after tax attributable to shareholders increased to ₹154.38 Cr compared to ₹134.71 Cr. Earnings Per Share (EPS) for the quarter stood at ₹7.85, an improvement from ₹6.84. These unaudited results provide key insights into the company's recent financial performance for shareholders.